1. P-463 Anti-Müllerian hormone levels in breast cancer patients receiving chemotherapy with or without concurrent luteinizing hormone-releasing hormone agonist: results from the PROMISE phase III trial. (30th June 2022) Authors: Marrocco, C; Conte, B; Rossi, G; Pirrone, C; Favero, D; Massarotti, C; Anserini, P; Fregatti, P; Cardinali, B; Buzzati, G; Levaggi, A; Poggio, F; Blondeaux, E; Del Mastro, L; Lambertini, M Journal: Human reproduction Issue: Volume 37(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗